These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 1621244)

  • 1. Biochemical and biological properties of a recombinant tissue-type plasminogen activator derived from the rat JMI-229 cell line.
    Lijnen HR; Webb PD; Van Hoef B; De Cock F; Stassen JM; Prior SD; Collen D
    Thromb Haemost; 1992 Feb; 67(2):239-47. PubMed ID: 1621244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical, thrombolytic and pharmacokinetic properties of rt-PA P47G, K49N, a substitution variant of human tissue-type plasminogen activator.
    Nelles L; Li XK; Vanlinthout I; De Cock F; Lijnen HR; Collen D
    Thromb Haemost; 1992 Apr; 67(4):445-52. PubMed ID: 1631793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of fibrin-like stimulators on the activation of plasminogen by tissue-type plasminogen activator (t-PA)--studies with active site mutagenized plasminogen and plasmin resistant t-PA.
    Lijnen HR; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1990 Aug; 64(1):61-8. PubMed ID: 2148848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical and biologic properties of rt-PA del (K296-G302), a recombinant human tissue-type plasminogen activator deletion mutant resistant to plasminogen activator inhibitor-1.
    Li XK; Lijnen HR; Nelles L; Van Hoef B; Stassen JM; Collen D
    Blood; 1992 Jan; 79(2):417-29. PubMed ID: 1730087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrin-specific thrombolytic agents.
    Collen D
    Klin Wochenschr; 1988; 66 Suppl 12():15-23. PubMed ID: 3126344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of plasminogen activator inhibitor-1 on tissue-type plasminogen activator-induced fibrinolysis.
    Carr ME; Krishnamurti C; Alving BM
    Thromb Haemost; 1992 Jan; 67(1):106-10. PubMed ID: 1615464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition in purified systems and in human plasma of chimaeric plasminogen activators consisting of the NH2-terminal region of tissue-type plasminogen activator and the COOH-terminal region of urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; De Cock F; Collen D
    Thromb Haemost; 1988 Oct; 60(2):247-50. PubMed ID: 3146141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of alpha 2-antiplasmin in fibrin-specific clot lysis with single-chain urokinase-type plasminogen activator in human plasma.
    Declerck PJ; Lijnen HR; Verstreken M; Collen D
    Thromb Haemost; 1991 Apr; 65(4):394-8. PubMed ID: 2057921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G; Pascucci C; Nenci GG; Mele A; Bürgi R; Heim J
    Thromb Haemost; 1993 Aug; 70(2):294-300. PubMed ID: 8236138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble fibrin degradation products potentiate tissue plasminogen activator-induced fibrinogen proteolysis.
    Weitz JI; Leslie B; Ginsberg J
    J Clin Invest; 1991 Mar; 87(3):1082-90. PubMed ID: 1900308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of clot lysis in vitro and in vivo with a bispecific monoclonal antibody directed against human fibrin and against urokinase-type plasminogen activator.
    Kurokawa T; Iwasa S; Kakinuma A; Stassen JM; Lijnen HR; Collen D
    Thromb Haemost; 1991 Dec; 66(6):684-93. PubMed ID: 1796414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells.
    Collen D; Stassen JM; Marafino BJ; Builder S; De Cock F; Ogez J; Tajiri D; Pennica D; Bennett WF; Salwa J
    J Pharmacol Exp Ther; 1984 Oct; 231(1):146-52. PubMed ID: 6541693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of domain deletion and/or duplication mutants of a recombinant chimera of tissue-type plasminogen activator and urokinase-type plasminogen activator (rt-PA/u-PA).
    Nelles L; Lijnen HR; Van Nuffelen A; Demarsin E; Collen D
    Thromb Haemost; 1990 Aug; 64(1):53-60. PubMed ID: 2148847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
    Collen D
    J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits.
    Krishnamurti C; Young GD; Barr CF; Colleton CA; Alving BM
    J Lab Clin Med; 1991 Dec; 118(6):523-30. PubMed ID: 1744501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen-dependent and -independent proteolytic activity of murine endothelioma cells with targeted inactivation of fibrinolytic genes.
    Lijnen HR; Wagner EF; Collen D
    Thromb Haemost; 1997 Feb; 77(2):362-7. PubMed ID: 9157597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effector roles of kringle 1 and kringle 2 in the enzymatic properties of recombinant tissue-type plasminogen activator as revealed by generation of recombinant molecules containing each kringle linked to the protease domain.
    Rydzewski A; Castellino FJ
    Arch Biochem Biophys; 1993 Jan; 300(1):472-82. PubMed ID: 8424682
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.